NegativeSec. CMS-2026-0089 · CMS Medicare Drug Price Negotiation
Medicare Part D Negotiation Methodology Update
12 NBC member drugs directly subject to revised methodology. Therapeutic value framework could result in steeper price reductions than originally projected — 45-65% vs. 40-60%.
ACTION: File coordinated public comments challenging therapeutic value methodology within 60-day window. Engage Cassidy-Menendez offices on small biotech exemption.
$4.8B estimated savings over 10 years
NegativeSec. CMS-2026-0142 · CMS Medicare Part B Payment Reform
Medicare Part B Drug Payment Rate Adjustment
NBC members with high-cost Part B drugs face 50% margin compression. Particularly devastating for oncology infusion drugs and rare disease biologics administered in outpatient settings.
ACTION: Activate physician advocacy coalition — oncologists and rheumatologists rely on Part B buy-and-bill model. Emphasize patient access impact.
Patent dance reform accelerates competitive threats to NBC member biologics. 6 members face earlier-than-expected biosimilar competition on $12B+ in combined revenue.
ACTION: Advocate for reasonable transition period in patent dance reform. Engage Collins office on innovation-preserving amendments.
$1.2B CBO-scored savings over 10 years
NegativeSec. S-2847 · Legislative — Drug Pricing
Prescription Drug Affordability Act
Federal upper payment limits would cap NBC member price increases. 18 member drugs had CPI-exceeding increases in 2025. Mandatory rebates estimated at $2.4B annually across membership.
ACTION: Priority opposition. Engage Cassidy on constitutional concerns with federal pricing authority. Commission economic impact study on R&D investment reduction.
$6.3B CBO-scored savings over 10 years
NegativeSec. CMS-2026-0178 · CMS IRA Drug Negotiation
IRA Drug Negotiation List Expansion (Round 3)
12 NBC member drugs on Round 3 list. Three members face existential risk with 40%+ revenue concentration in listed products. Combined revenue exposure: $5.2B.
ACTION: Convene emergency coalition meeting. Activate Cassidy-Menendez small biotech amendment. Brief all affected members within 48 hours.